Education
About Us
Working with TipRanks
Follow Us
Eris Lifesciences Ltd (IN:ERIS)
:ERIS
Total Valuation
Eris Lifesciences Ltd has a market cap or net worth of ₹230.27B. The enterprise value is ₹86.00B.
Market Cap₹230.27B
Enterprise Value₹86.00B
Share Statistics
Eris Lifesciences Ltd has 136,185,030 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding136,185,030
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Eris Lifesciences Ltd’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 6.90%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)6.90%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.28
Inventory Turnover5.27
Valuation Ratios
The current PE Ratio of Eris Lifesciences Ltd is 29.50. Eris Lifesciences Ltd’s PEG ratio is -3.40.
PE Ratio29.50
PS Ratio0.00
PB Ratio3.54
Price to Fair Value4.47
Price to FCF-14.15
Price to Operating Cash Flow26.67
PEG Ratio-3.40
Income Statement
In the last 12 months, Eris Lifesciences Ltd had revenue of 19.91B and earned 3.92B in profits. Earnings per share was 28.82.
Revenue19.91B
Gross Profit9.95B
Operating Income4.95B
Pretax Income4.31B
Net Income3.92B
EBITDA6.99B
Earnings Per Share (EPS)28.82
Cash Flow
In the last 12 months, operating cash flow was 1.76B and capital expenditures 0.00, giving a free cash flow of 1.76B billion.
Operating Cash Flow1.76B
Free Cash Flow1.76B
Free Cash Flow per Share12.90
Dividends & Yields
Eris Lifesciences Ltd pays an annual dividend of ₹7.349, resulting in a dividend yield of 0.43%
Dividend Per Share₹7.349
Dividend Yield0.43%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change69.04%
50-Day Moving Average1.48K
200-Day Moving Average1.37K
Relative Strength Index (RSI)73.26
Average Volume (3m)7.13K
Important Dates
Eris Lifesciences Ltd upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 19, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend DateFeb 13, 2025
Financial Position
Eris Lifesciences Ltd as a current ratio of 0.91, with Debt / Equity ratio of 39.92%
Current Ratio0.91
Quick Ratio0.83
Debt to Market Cap0.24
Net Debt to EBITDA3.85
Interest Coverage Ratio5.84
Taxes
In the past 12 months, Eris Lifesciences Ltd has paid 341.85M in taxes.
Income Tax341.85M
Effective Tax Rate0.08
Enterprise Valuation
Eris Lifesciences Ltd EV to EBITDA ratio is 20.39, with an EV/FCF ratio of 39.93.
EV to Sales7.16
EV to EBITDA20.39
EV to Free Cash Flow39.93
EV to Operating Cash Flow29.32
Balance Sheet
Eris Lifesciences Ltd has ₹14.01B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹14.01B billion.
Cash & Marketable Securities₹14.01B
Total Debt₹0.00
Net Cash-₹14.01B
Net Cash Per Share-₹102.85
Tangible Book Value Per Share-₹44.22
Margins
Gross margin is 78.80%, with operating margin of 24.87%, and net profit margin of 19.68%.
Gross Margin78.80%
Operating Margin24.87%
Pretax Margin21.66%
Net Profit Margin19.68%
EBITDA Margin35.08%
EBIT Margin25.91%
Analyst Forecast
The average price target for Eris Lifesciences Ltd is ₹1,780.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹1,780.00
Price Target Upside23.32% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―